What is PredictImmune?
Founded in 2017, PredictImmune operates at the intersection of immunology and diagnostic technology. The company specializes in creating prognostic tests that provide clinicians with actionable insights into the progression of immune-mediated diseases. By identifying patient-specific risk profiles, PredictImmune enables more informed therapeutic decisions, potentially reducing the burden of ineffective treatments and improving long-term patient outcomes. Its market position is bolstered by its roots in the UK academic ecosystem, allowing it to translate high-level scientific discovery into scalable, enterprise-level healthtech products.
How much funding has PredictImmune raised?
PredictImmune has raised a total of $16.6M across 2 funding rounds:
Series A
$5.9M
Series B
$10.7M
Series A (2018): $5.9M with participation from The Wellcome Trust
Series B (2019): $10.7M led by BFG and Parkwalk
Key Investors in PredictImmune
Parkwalk
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities. They bridge the gap between academic research and commercial success by providing funding, expertise, and networks to help these companies thrive.
The Wellcome Trust
Wellcome is an independent global charitable foundation based in London that supports discovery research and tackles urgent health challenges, funding science, policy and public engagement to improve health for people everywhere.
BFG
An institutional investor participating in the growth financing of high-potential healthtech ventures.
What's next for PredictImmune?
With the successful completion of its latest financing round, PredictImmune is expected to focus on the international scaling of its diagnostic portfolio. The strategic roadmap likely includes expanding clinical validation studies and strengthening its commercial infrastructure to support wider adoption within healthcare systems. As the company matures, the focus will shift toward integrating its prognostic tools into standard clinical workflows, thereby solidifying its role as a key player in the global precision medicine market. Continued investment in R&D will remain a priority to ensure the company maintains its competitive edge in the rapidly evolving landscape of immune-mediated disease management.
See full PredictImmune company page
